Sutro Biopharma STRO EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Sutro Biopharma’s reported figures.
Based on trailing twelve months.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's EBITDA margin?
- Sutro Biopharma (STRO) reported EBITDA margin of -113.3% in Q1 2026.
- How has Sutro Biopharma's EBITDA margin changed year-over-year?
- Sutro Biopharma's EBITDA margin increased by 69.0% year-over-year, from -365.8% to -113.3%.
- What is the long-term trend for Sutro Biopharma's EBITDA margin?
- Over 4 years (2020 to 2025), Sutro Biopharma's EBITDA margin has grown at a -1.5% compound annual growth rate (CAGR), from -156.3% to -147.4%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.